Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Curaleaf enhances offer to acquire Aurora Cannabis (SeekingAlpha) +++ AURORA CANNABIS Aktie +6,09%

TUHURA Aktie

 >TUHURA Aktienkurs 
1.72 EUR    (TradegateBSX)
Ask: 1.75 EUR / 2850 Stück
Bid: 1.69 EUR / 2970 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
TUHURA Aktie über LYNX handeln
>TUHURA Performance
1 Woche: -7,6%
1 Monat: -4,5%
3 Monate: -22,0%
6 Monate: +37,1%
1 Jahr: -24,1%
laufendes Jahr: +153,7%
>TUHURA Aktie
Name:  TUHURA BIOSCIENCES INC.
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US8989201038 / A3EWMJ
Symbol/ Ticker:  PL3 (Frankfurt) / HURA (NASDAQ)
Kürzel:  FRA:PL3, ETR:PL3, PL3:GR, NASDAQ:HURA
Index:  -
Webseite:  https://tuhurabio.com/
Profil:  TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapies designed to overcome resistance to cancer immunotherapy. The company’s current pipeline centers on immune-modulating product candidates, incl..
>Volltext..
Marktkapitalisierung:  108.14 Mio. EUR
Unternehmenswert:  111.06 Mio. EUR
Umsatz:  -
EBITDA:  -27.83 Mio. EUR
Nettogewinn:  -27.21 Mio. EUR
Gewinn je Aktie:  -0.47 EUR
Schulden:  3.56 Mio. EUR
Liquide Mittel:  0.88 Mio. EUR
Operativer Cashflow:  -26.38 Mio. EUR
Bargeldquote:  0.11
Umsatzwachstum:  -
Gewinnwachstum:  -10.3%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  TUHURA
Letzte Datenerhebung:  05.10.26
>TUHURA Kennzahlen
Aktien/ Unternehmen:
Aktien: 63.73 Mio. St.
Frei handelbar: 65.38%
Leerverk. Aktien: 9.85%
Rückkaufquote: -15.28%
Mitarbeiter: 22
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 320.94%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 6.68
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -92.29%
Eigenkaprendite: -161.39%
>TUHURA Peer Group
Gesundheit, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika
 
05.10.26 - 13:48
 TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology (PR Newswire)
 
Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company......
14.09.26 - 13:54
 TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers (PR Newswire)
 
TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA)......
08.09.26 - 13:51
 TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
 
TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief......
14.08.26 - 14:00
 TuHURA Biosciences reports Q2 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.08.26 - 13:48
 TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update (PR Newswire)
 
TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter......
12.08.26 - 19:25
 TuHURA auf der Canaccord-Wachstumskonferenz: Strategie für Spätphasen­entwicklung gewinnt an Fahrt (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
22.07.26 - 13:42
 TuHURA Biosciences to Present at Canaccord Genuity′s 46th Annual Growth Conference (PR Newswire)
 
TAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief......
15.06.26 - 13:51
 TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers (PR Newswire)
 
The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for Acute Myeloid Leukemia (AML) The FDA noted that the requested meeting would not be necessary and......
15.05.26 - 23:33
 TuHURA Biosciences reports Q1 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.05.26 - 23:03
 TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update (PR Newswire)
 
TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter......
12.05.26 - 13:33
 TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference (PR Newswire)
 
TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced James A. Bianco, M.D., President and Chief......
22.04.26 - 14:39
 TuHURA Biosciences secures $50 million credit facility, extends cash runway to 2028 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.04.26 - 13:33
 TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 (PR Newswire)
 
Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestones TAMPA, Fla., April 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3......
07.04.26 - 13:48
 TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations (PR Newswire)
 
Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development TAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome......
01.04.26 - 14:09
 TuHURA Biosciences reports FY results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.04.26 - 13:48
 TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update (PR Newswire)
 
TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's fourth quarter......
23.03.26 - 12:48
 Craig Tendler, M.D., JNJ′s Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience′s VISTA Program in AML and other Blood Related Cancers (PR Newswire)
 
Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four......
27.02.26 - 16:54
 TuHURA Biosciences: Aktie legt nach Erfüllung der NASDAQ-Anforderungen zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
27.02.26 - 13:33
 TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
 
TAMPA, Fla., Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26, 2026, it received written......
24.02.26 - 23:24
 TuHURA Biosciences Announces Participation in Upcoming Investor Conferences (PR Newswire)
 
TAMPA, Fla., Feb. 24, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Dr. James Bianco, President and Chief......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Um einen Graben zu füllen, muß ein Hügel abgetragen werden. - Sprichwort Armenien
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!